Oxford Immunotec Reports First Quarter 2016 Financial Results
- First quarter revenue of $17.1 million, increased 24% compared to prior year period
- Over 7 million cumulative tests sold through the end of the quarter
OXFORD, United Kingdom and MARLBOROUGH, Mass., May 03, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced first quarter 2016 financial results.
“We are very happy with our first quarter financial and operating results,” said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. "Our sales performance was in line with our expectations, with solid growth coming from our United States and Asia geographies.”
By revenue type, total revenues were, in millions:
|Three Months Ended March 31,|
By geography, total revenues were, in millions:
|Three Months Ended March 31,|
|Europe & ROW||1.6||1.7||-8||%||-3||%|
(1) We evaluate our revenue on both an as reported and a constant currency basis. The constant currency presentation, which is a non-GAAP measure, excludes the impact of fluctuations in foreign currency exchange rates.
First Quarter 2016 Financial Results
Revenue for the first quarter of 2016 was $17.1 million, representing 24% growth over the first quarter 2015 revenue of $13.8 million. On a constant currency basis, revenue growth was 23% versus the prior year period.
2016 first quarter product revenue was $8.1 million representing a 14% increase from product revenue of $7.1 million in the first quarter of 2015. The increase in product revenue was primarily attributable to growth in Asia. Service revenue for the first quarter of 2016 was $9.0 million, up 34% from the 2015 first quarter revenue of $6.7 million. The increase in service revenue was primarily driven by growth in the United States.
United States revenue was $8.7 million in the first quarter of 2016 representing 37% growth over the same period's revenue of $6.4 million in the prior year. Growth was driven primarily by volume increases in the institutional and patient testing segments.
Europe & ROW revenue was $1.6 million in the first quarter of 2016 representing an 8% decrease compared to first quarter of 2015. On a constant currency basis, Europe & ROW decreased 3% versus the first quarter of 2015.
Asia revenue was $6.8 million in the first quarter of 2016 representing 19% growth over 2015 first quarter revenue of $5.7 million. On a constant currency basis, Asia grew 15% versus the first quarter of 2015. The increase was driven by continued strong growth in Japan. China growth was more muted due to the timing of orders in 2015.
Gross profit for the first quarter of 2016 was $8.9 million, an increase of $1.8 million over gross profit of $7.1 million in the same period of 2015. Gross margin was 52.3%, an increase of 50 basis points from the gross margin of 51.8% in the first quarter of 2015. The increase in gross margin was primarily due to mix and lower kit costs associated with increased volume, offset by the costs associated with ongoing process refinement in our Memphis laboratory as well as the ongoing investment into broadening our service capabilities.
Operating expenses were $16.1 million in the first quarter of 2016, an increase of $2.4 million compared to $13.7 million in the same period last year. The increase in operating expenses was primarily due to headcount increases related to both sales and marketing and general and administrative functions, as well as increased costs from clinical studies performed during the quarter.
EBITDA for the fourth quarter was $(6.4) million compared to $(5.8) million in the first quarter of 2015. Adjusted EBITDA was $(5.8) million for the first quarter compared to $(5.0) million in the same period in 2015. Both EBITDA and Adjusted EBITDA are non-GAAP measures.
Net loss for the first quarter of 2016 was $7.0 million, or $0.32 per share, compared to $6.3 million, or $0.31 per share, in the first quarter of 2015. Net loss per share was based on 22,284,392 and 20,331,411 weighted average ordinary shares outstanding for the first quarters of 2016 and 2015, respectively.
Cash and cash equivalents were $68.7 million as of March 31, 2016 compared to $83.7 million as of December 31, 2015. Cash usage during the quarter was in line with expectations. The first quarter typically has the highest cash usage as a result of the pre-payment of royalties and payment of year-end bonuses.
We expect to report full year 2016 revenue of between $74 and $77 million, representing 18%-23% year-over-year growth.
We expect to report revenue of between $17.4 and $18.2 million for the second quarter of 2016.
Oxford Immunotec will host a conference call on Tuesday, May 3, 2016 at 8:00 a.m. Eastern Time to discuss its first quarter 2016 financial results. The call will be concurrently webcast. To listen to the conference call on your telephone please dial (855) 363-5047 for United States callers and +1 (484) 365-2897 for international callers and reference confirmation code 89843505 approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at www.oxfordimmunotec.com. The replay will be available on the Company's website for approximately 60 days.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions. The Company's first product is the T-SPOT®.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The T-SPOT.CMV test and the T-SPOT.PRT test are the Company's second and third products and part of a series of products intended for the transplantation market. In addition to these three products, the Company has an additional six active development programs, each of which leverages our T cell, B cell and innate immune measuring technology. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found atwww.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.
This release contains forward-looking statements, including statements regarding future revenues, expenses and the prospects for sales of our products. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, decisions by regulatory authorities, hospitals and other health care institutions, laboratories, physicians, patients and third party payers, as well as our ability to expeditiously and successfully expand our sales and distribution networks and the other factors described under the "Risk Factors" section in our filings with the Securities and Exchange Commission. When evaluating Oxford Immunotec's business and securities, investors should give careful consideration to these risks and uncertainties.
Forward-looking statements are based on current expectations and assumptions and currently available data and are neither predictions nor guarantees of future events or performance. You should not place undue reliance on forward-looking statements, which speak only as of the date of this presentation. We do not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law.
For Media Inquiries:
Tel: +44 1235 442796
For Investor Inquiries:
Chief Financial Officer
Tel: +1 (508) 573-9953
Tel: +1 (443) 213-0501
|Oxford Immunotec Global PLC|
|Condensed consolidated statements of operations|
|Three months ended March 31,|
|(in thousands, except share and per share data)||2016||2015|
|Cost of revenue|
|Total cost of revenue||8,165||6,655|
|Research and development||3,076||2,359|
|Sales and marketing||8,480||7,441|
|General and administrative||4,583||3,867|
|Total operating expenses||16,139||13,667|
|Loss from operations||(7,194||)||(6,521||)|
|Other income (expense):|
|Interest expense, net||(17||)||(15||)|
|Foreign exchange gains||363||165|
|Other (expense) income||(166||)||107|
|Loss before income taxes||(7,014||)||(6,264||)|
|Income tax expense||35||47|
|Net loss per share attributable to ordinary shareholders—basic and diluted||$||(0.32||)||$||(0.31||)|
|Weighted-average shares used to compute net loss attributable to ordinary shareholders—basic and diluted||22,284,392||20,331,411|
|Reconciliation of net loss to Adjusted EBITDA (1)|
|Three months ended March 31,|
|Income tax expense||35||47|
|Interest expense, net||17||15|
|Depreciation and amortization||581||453|
|Share-based compensation expense||1,104||875|
|Unrealized exchange gains||(522||)||(156||)|
|Change in fair value of contingent purchase price consideration||55||47|
(1) Adjusted EBITDA is a non-GAAP measure that we calculate as net loss, adjusted for the impact of earnings or charges resulting from matters that we consider not to be indicative of our ongoing operations. We believe that Adjusted EBITDA provides useful information to investors in understanding and evaluating our operating results in the same manner as our management and Board of Directors. Our presentation of Adjusted EBITDA is not made in accordance with U.S. GAAP, and our computation of Adjusted EBITDA may vary from others in the industry. Our use of Adjusted EBITDA has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our results as reported under U.S. GAAP.
The above table presents a reconciliation of net loss, the most comparable U.S. GAAP measure, to Adjusted EBITDA for each of the periods indicated.
|Oxford Immunotec Global PLC|
|Condensed consolidated balance sheets|
|March 31,||December 31,|
|(in thousands, except share and per share data)||2016||2015|
|Cash and cash equivalents||$||68,731||$||83,715|
|Accounts receivable, net||8,427||7,058|
|Prepaid expenses and other||3,439||3,592|
|Total current assets||89,076||101,464|
|Restricted cash, non-current||80||80|
|Property and equipment, net||6,526||6,284|
|In-process research and development||1,855||1,782|
|Other intangible assets, net||163||179|
|Liabilities and shareholders’ equity|
|Current portion of loans payable||80||79|
|Total current liabilities||9,566||15,481|
|Long-term portion of loans payable||366||386|
|Contingent purchase price consideration||1,403||1,293|
|Ordinary shares, £0.006705 nominal value; 36,183,293 shares authorized at March 31, 2016 and December 31, 2015, and 22,566,475 and 22,549,488 shares issued and outstanding at March 31, 2016 and December 31, 2015, respectively||243||243|
|Additional paid-in capital||245,148||244,033|
|Accumulated other comprehensive loss||(5,603||)||(5,277||)|
|Total shareholders’ equity||86,432||92,692|
|Total liabilities and shareholders’ equity||$||97,767||$||109,852|
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Dog Meat Free Indonesia : Sickening animal cruelty at Indonesia's "extreme" markets where dogs and cats are bludgeoned, blowtorched alive24.1.2018 09:30 | Pressemelding
Government urged to take immediate action to protect animals and public health LONDON, Jan. 24, 2018 (GLOBE NEWSWIRE) -- The Indonesian government is being urged to shut down the country's cruel live animal markets, where thousands of dogs and cats a week are bludgeoned in public, blowtorched whilst still alive, and butchered for eating. Campaigners from the Dog Meat-Free Indonesia coalition filmed at two of the most notorious of Indonesia's 200 live animal markets in North Sulawesi, "Tomohon Extreme Market" and Langowan Market, to expose the horrifying suffering routinely endured by animals. Live dogs and cats are seen trembling in cages as one by one they are beaten over the head, howling in pain. Lola Webber, Dog Meat-Free Indonesia campaign coordinator, said: " It was like walking through hell. The dogs huddled together in cages , trembling with fear as they watched others being killed around them , waiting their turn. The sight of absolute terror in their eyes, the thumping of the
Promethean Expands Educational Display Portfolio to Create Immersive Classroom Experiences24.1.2018 09:18 | Pressemelding
Seattle, Wash., Jan. 24, 2018 (GLOBE NEWSWIRE) -- Promethean TM, a global education technology company, announced expansions to its interactive flat panel portfolio which includes the market-leading ActivPanel and ActivPanel i-Series. The ActivPanel continues to offer the industry's most natural writing experience using InGlassTM technology, enabling both teachers and students to collaborate in front of the class with ease. The ActivPanel i-Series is an essential interactive flat panel for customers looking to replace their projector-based systems with a long-term, reliable solution. "Educators want technology that works as they do - flexible and able to adapt to their teaching styles in any classroom setting," said Ravi Angadi, Chief Products and Strategy Officer, Promethean. "At Promethean, we strive to create a dynamic ecosystem to enhance teacher productivity, providing educators with the latest innovative education technologies that are intuitive and immersive. With access to an e
Leading Medical Organizations Update Guideline for Molecular Testing and Targeted Therapies in Lung Cancer23.1.2018 21:11 | Pressemelding
DENVER, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Rapid advancements in the molecular diagnostic testing of lung cancer have led to new treatments and greater hope for patients battling lung cancer, the most common cause of cancer death worldwide. To ensure that clinicians stay apace and provide optimal patient care, three leading medical societies-the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP)-have updated their 2013 evidence-based guideline. Published today in early online release, the "Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors," continues to set standards for the molecular analysis of lung cancers for test results that effectively guide targeted therapy and treatment. Targeted cancer therapies are drugs or other treatments that block the spread of cancer by interfering with specific molec
CashBet Seeks $40 Million for World's Only Complete Crypto-Ready Mobile iGaming Platform23.1.2018 16:31 | Pressemelding
Gaming and cryptocurrency industry leaders develop blockchain-based iGaming platform improving trust, speed, access, costs, and content availability OAKLAND, Calif., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Leading mobile-first iGaming platform provider CashBet (https://coin.cashbet.com/) today announced it seeks to raise $40 million through an Initial Coin Offering (ICO) to develop the world's first complete crypto-ready mobile iGaming platform. Interactive gaming, which includes real money, social, skill-based, esports and sports betting, hit $91 billion in 2016, led by mobile gaming. Despite strong growth, current iGaming operations continue to face three major issues: trust, speed, and cost. CashBet is the first and only vertically integrated iGaming solution to leverage blockchain technology for transparent operations, increased speed, and lower transaction fees. The CashBet Coin will be available in pre-sale starting January 24, 2018 at 5:00 p.m. GMT, with a 20 percent discount offered.
BrandSafway Announces Acquisition of Venko Groep BV23.1.2018 16:30 | Pressemelding
Combined customers to benefit from broader range of services and greater depth of expertise KENNESAW, GA, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Brand Industrial Services, known as BrandSafway, has acquired Venko Groep BV, a portfolio company of Mentha Capital, effective January 1, 2018. Moving forward, the company will operate as Venko, A BrandSafway Company and become a part of Brand Energy & Infrastructure Services (Brand) in Europe. "We're excited to announce the closing of the acquisition of Venko," said Dave Witsken, President of Energy and Industrial for BrandSafway. "Venko is a leading offshore coatings maintenance provider for platforms in Europe. By leveraging the highly specialized knowledge and capabilities of Venko, we will be able to provide expanded coatings services to Brand's European customers. At the same time, with our support, Venko will now be able to offer their customers a broader inventory of access equipment and additional industrial services, such as insulation an
Mitratech's TeamConnect Rated Most Widely Used Matter Management System in HBR Consulting's Annual Law Department Survey23.1.2018 15:00 | Pressemelding
HBR's Annual Survey further validates TeamConnect's market leadership AUSTIN, Texas, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Mitratech, the leading provider of legal, compliance, and risk management software solutions announced that TeamConnect, the market-leading ELM (enterprise legal management) platform, was rated the most widely used matter management system and the second most widely used e-Billing system in the 2017 HBR Consulting (HBR) Law Department Survey. HBR's Law Department Survey released this month rated Mitratech's TeamConnect as the most widely used system for matter management out of the 13 systems included in the survey. All told, Mitratech's ELM solutions accounted for more than a third of the matter management user base. TeamConnect also was rated for the third year in a row as the second most widely used e-Billing system, continuing a years-long trend of customers shifting to Mitratech's integrated ELM platform from other point solutions. Customer satisfaction continues
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom